Exact Mass: 1084.5817798

Exact Mass Matches: 1084.5817798

Found 34 metabolites which its exact mass value is equals to given mass value 1084.5817798, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

AzIV

5-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,4-dihydroxy-6-({9-[(5-hydroxy-6-methyl-4-oxo-3,4-dihydro-2H-pyran-2-yl)oxy]-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl}oxy)oxane-2-carboxylic acid

C54H84O22 (1084.5453964)


Soyasaponin ag is found in pulses. Soyasaponin ag is a constituent of scarlet runner bean (Phaseolus coccineus) seeds. Constituent of scarlet runner bean (Phaseolus coccineus) seeds. Soyasaponin ag is found in soy bean and pulses.

   

PIP(22:2(13Z,16Z)/6 keto-PGF1alpha)

{[(1S,6R,15S,16S,18R,19S,20R,21R,22R,23S,24R)-6-{[(13Z,16Z)-docosa-13,16-dienoyloxy]methyl}-3,16,18,20,22,23,24-heptahydroxy-19-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3,8,13-trioxo-2,4,7-trioxa-3lambda5-phosphabicyclo[13.6.3]tetracosan-21-yl]oxy}phosphonic acid

C51H90O20P2 (1084.5500399999999)


PIP(22:2(13Z,16Z)/6 keto-PGF1alpha) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:2(13Z,16Z)/6 keto-PGF1alpha), in particular, consists of one chain of 13Z,16Z-docosadienoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(6 keto-PGF1alpha/22:2(13Z,16Z))

{[(1S,6R,16S,17S,19R,20S,21R,22R,23R,24S,25R)-6-[(13Z,16Z)-docosa-13,16-dienoyloxy]-3,17,19,21,23,24,25-heptahydroxy-20-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3,9,14-trioxo-2,4,8-trioxa-3lambda5-phosphabicyclo[14.6.3]pentacosan-22-yl]oxy}phosphonic acid

C51H90O20P2 (1084.5500399999999)


PIP(6 keto-PGF1alpha/22:2(13Z,16Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(6 keto-PGF1alpha/22:2(13Z,16Z)), in particular, consists of one chain of 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 13Z,16Z-docosadienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:2(13Z,16Z)/TXB2)

{[(1S,6R,12Z,15S,16S,20R,21R,22R,23R,24S,25R)-6-{[(13Z,16Z)-docosa-13,16-dienoyloxy]methyl}-3,16,18,21,23,24,25-heptahydroxy-20-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3,8-dioxo-2,4,7,19-tetraoxa-3lambda5-phosphabicyclo[13.7.3]pentacos-12-en-22-yl]oxy}phosphonic acid

C51H90O20P2 (1084.5500399999999)


PIP(22:2(13Z,16Z)/TXB2) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:2(13Z,16Z)/TXB2), in particular, consists of one chain of 13Z,16Z-docosadienoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(TXB2/22:2(13Z,16Z))

{[(1S,6R,13Z,16S,17S,21R,22R,23R,24R,25S,26R)-6-[(13Z,16Z)-docosa-13,16-dienoyloxy]-3,17,19,22,24,25,26-heptahydroxy-21-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3,9-dioxo-2,4,8,20-tetraoxa-3lambda5-phosphabicyclo[14.7.3]hexacos-13-en-23-yl]oxy}phosphonic acid

C51H90O20P2 (1084.5500399999999)


PIP(TXB2/22:2(13Z,16Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(TXB2/22:2(13Z,16Z)), in particular, consists of one chain of Thromboxane B2 at the C-1 position and one chain of 13Z,16Z-docosadienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   
   
   
   
   

lineolon 3-O-beta-D-oleandropyranosyl-(1->4)-beta-D-cymaropyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-oleandropyranoside

lineolon 3-O-beta-D-oleandropyranosyl-(1->4)-beta-D-cymaropyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-oleandropyranoside

C56H92O20 (1084.6181632)


   
   

3-O-[beta-D-galactopyranosyl(1->2)]-alpha-L-arabinofuranosyl(1->3)-beta-D-glucuronopyranosyl-21-O-angeloyl-22-O-acetyl-3beta,16alpha,21beta,22alpha,28-pentahydroxyolean-12-ene|aesculioside IIk

3-O-[beta-D-galactopyranosyl(1->2)]-alpha-L-arabinofuranosyl(1->3)-beta-D-glucuronopyranosyl-21-O-angeloyl-22-O-acetyl-3beta,16alpha,21beta,22alpha,28-pentahydroxyolean-12-ene|aesculioside IIk

C54H84O22 (1084.5453964)


   

(3beta,4beta,21beta,22alpha)-22-(acetyloxy)-3-{{O-alpha-L-arabinopyranosyl-(1->4)-O-[beta-D-glucopyranosyl-(1->2)]-beta-D-glucopyranosyl}oxy}-23-hydroxy-21-{[(2Z)-2-methyl-1-oxobut-2-en-1-yl]oxy}-olean-12-en-28-oic acid|22-O-acetyl-21-O-angeloyl-3-O-{O-alpha-L-arabinopyranosyl-(1->4)-O-[beta-D-glucopyranosyl-(1->2)]-beta-D-glucopyranosyl}-24-hydroxyacerogenic acid|dipteroside A

(3beta,4beta,21beta,22alpha)-22-(acetyloxy)-3-{{O-alpha-L-arabinopyranosyl-(1->4)-O-[beta-D-glucopyranosyl-(1->2)]-beta-D-glucopyranosyl}oxy}-23-hydroxy-21-{[(2Z)-2-methyl-1-oxobut-2-en-1-yl]oxy}-olean-12-en-28-oic acid|22-O-acetyl-21-O-angeloyl-3-O-{O-alpha-L-arabinopyranosyl-(1->4)-O-[beta-D-glucopyranosyl-(1->2)]-beta-D-glucopyranosyl}-24-hydroxyacerogenic acid|dipteroside A

C54H84O22 (1084.5453964)


   

3-O-[beta-D-galactopyranosyl-(1?2)]-alpha-L-rhamnopyranosyl-(1?3)-beta-D-glucopyranosyl-21beta-tigloyl-22alpha-acetyl-3beta,16alpha,21beta,22alpha,28-pentahydroxyolean-12-ene|aesculioside C6

3-O-[beta-D-galactopyranosyl-(1?2)]-alpha-L-rhamnopyranosyl-(1?3)-beta-D-glucopyranosyl-21beta-tigloyl-22alpha-acetyl-3beta,16alpha,21beta,22alpha,28-pentahydroxyolean-12-ene|aesculioside C6

C55H88O21 (1084.5817798)


   

3-O-[beta-D-galactopyranosyl-(1?2)]-alpha-L-rhamnopyranosyl-(1?3)-beta-D-glucopyranosyl-21beta-tigloyl-28-acetyl-3beta,16alpha,21beta,22alpha,28-pentahydroxyolean-12-ene|aesculioside C8

3-O-[beta-D-galactopyranosyl-(1?2)]-alpha-L-rhamnopyranosyl-(1?3)-beta-D-glucopyranosyl-21beta-tigloyl-28-acetyl-3beta,16alpha,21beta,22alpha,28-pentahydroxyolean-12-ene|aesculioside C8

C55H88O21 (1084.5817798)


   

3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(11-methyltridecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide

NCGC00384896-01!3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(11-methyltridecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide

C51H80N12O14 (1084.591666)


   

pergularin 3-O-alpha-cymaropyranosyl-(1->4)-beta-cymaropyranosyl-(1->4)-alpha-cymaropyranosyl-(1->4)-beta-cymaropyranosyl-(1->4)-beta-cymaropyranoside

pergularin 3-O-alpha-cymaropyranosyl-(1->4)-beta-cymaropyranosyl-(1->4)-alpha-cymaropyranosyl-(1->4)-beta-cymaropyranosyl-(1->4)-beta-cymaropyranoside

C56H92O20 (1084.6181632)


   
   

AzIV

5-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,4-dihydroxy-6-({9-[(5-hydroxy-6-methyl-4-oxo-3,4-dihydro-2H-pyran-2-yl)oxy]-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl}oxy)oxane-2-carboxylic acid

C54H84O22 (1084.5453964)


   
   

Bremelanotide Acetate

Bremelanotide Acetate

C52H72N14O12 (1084.5453872)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D009074 - Melanocyte-Stimulating Hormones C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone Bremelanotide Acetate (PT-141 Acetate), a synthetic peptide analogue of α-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R for the treatment of sexual dysfunction[1].

   
   
   
   
   
   

6-[(4-methoxy-5-{[4-methoxy-5-({4-methoxy-5-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl)oxy]-9,13,18-trimethyl-19,20-dioxapentacyclo[10.7.1.0¹,¹⁰.0⁴,⁹.0¹³,¹⁷]icos-3-en-14-one

6-[(4-methoxy-5-{[4-methoxy-5-({4-methoxy-5-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl)oxy]-9,13,18-trimethyl-19,20-dioxapentacyclo[10.7.1.0¹,¹⁰.0⁴,⁹.0¹³,¹⁷]icos-3-en-14-one

C55H88O21 (1084.5817798)


   

(3r,4r,4as,6as,6br,8ar,9s,10s,12ar,12br,14bs)-4-(acetyloxy)-10-{[(2r,3r,4s,5s,6r)-4-hydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-3-{[(2z)-2-methylbut-2-enoyl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(3r,4r,4as,6as,6br,8ar,9s,10s,12ar,12br,14bs)-4-(acetyloxy)-10-{[(2r,3r,4s,5s,6r)-4-hydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-3-{[(2z)-2-methylbut-2-enoyl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C54H84O22 (1084.5453964)


   

1-[(1r,3ar,3bs,7s,9ar,9br,11r,11as)-3a,3b,11-trihydroxy-7-{[(2r,4r,5r,6r)-5-{[(2s,4r,5r,6r)-5-{[(2s,4r,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1r,3ar,3bs,7s,9ar,9br,11r,11as)-3a,3b,11-trihydroxy-7-{[(2r,4r,5r,6r)-5-{[(2s,4r,5r,6r)-5-{[(2s,4r,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C56H92O20 (1084.6181632)


   

1-[(1s,3as,3br,7s,9ar,9bs,11r,11as)-1,3a,11-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5s,6s)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1s,3as,3br,7s,9ar,9bs,11r,11as)-1,3a,11-trihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5s,6s)-5-{[(2s,4s,5r,6r)-5-{[(2s,4r,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C56H92O20 (1084.6181632)


   

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(12-methyltridecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(12-methyltridecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C51H80N12O14 (1084.591666)


   

(5r,8s,11r,12s,15s,18s,19s,22r)-15-(3-carbamimidamidopropyl)-3,6,9,13,16,20-hexahydroxy-18-[(1e,3e,5s,6s)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-1,12,19-trimethyl-2-methylidene-5-(2-methylpropyl)-25-oxo-8-(2-phenylethyl)-1,4,7,10,14,17,21-heptaazacyclopentacosa-3,6,9,13,16,20-hexaene-11,22-dicarboxylic acid

(5r,8s,11r,12s,15s,18s,19s,22r)-15-(3-carbamimidamidopropyl)-3,6,9,13,16,20-hexahydroxy-18-[(1e,3e,5s,6s)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-1,12,19-trimethyl-2-methylidene-5-(2-methylpropyl)-25-oxo-8-(2-phenylethyl)-1,4,7,10,14,17,21-heptaazacyclopentacosa-3,6,9,13,16,20-hexaene-11,22-dicarboxylic acid

C56H80N10O12 (1084.595688)